GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AMX0035

AMX0035

Company
University of Washington
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for AMX0035 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07699380

    METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

    Not yet reported University of Washington 60 participants Est. completion 2029-12 2 sites Stand-alone
    Other conditions: Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
    View official trial listing →
  • Completed NCT NCT03127514

    AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported Amylyx Pharmaceuticals Inc. 137 participants Est. completion 2019-11-24 25 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
    View official trial listing →
  • Completed NCT NCT03488524

    Open Label Extension Study of AMX0035 in Patients With ALS

    Not yet reported Amylyx Pharmaceuticals Inc. 90 participants Est. completion 2021-03-01 24 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis, ALS
    View official trial listing →
  • Completed NCT NCT03533257

    Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

    Not yet reported Amylyx Pharmaceuticals Inc. 95 participants Est. completion 2020-11-06 11 sites
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT04516096

    A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported, Not yet reported Amylyx Pharmaceuticals Inc. 28 participants Est. completion 2023-01-31 5 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Status unknown NCT NCT04987671

    Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

    Not yet reported, Not yet reported Amylyx Pharmaceuticals Inc. 14 participants Est. completion 2023-09 1 site Stand-alone
    Other conditions: ALS
    View official trial listing →
  • Status unknown NCT NCT05021536

    Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

    Not yet reported Amylyx Pharmaceuticals Inc. 664 participants Est. completion 2026-01-01 69 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Approved For Marketing NCT NCT05286372

    An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

    Amylyx Pharmaceuticals Inc. 21 sites
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT05619783

    Extension Study Evaluating The Safety And Tolerability of AMX0035

    Not yet reported Amylyx Pharmaceuticals Inc. 352 participants Est. completion 2024-10-30 46 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT05676034

    AMX0035 in Adult Patients With Wolfram Syndrome

    Not yet reported Amylyx Pharmaceuticals Inc. 12 participants Est. completion 2028-05-31 1 site Stand-alone
    Other conditions: Wolfram Syndrome
    View official trial listing →
  • Completed NCT NCT06122662

    AMX0035 and Progressive Supranuclear Palsy

    Not yet reported, Not yet reported Amylyx Pharmaceuticals Inc. 139 participants Est. completion 2025-10-21 62 sites Stand-alone
    Other conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.